How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis
Overview
Discover how Ebglyss (Lebrikizumab) works as a targeted IL-13 inhibitor in the treatment of Atopic Dermatitis (AD). Learn more about Ebglyss unique mechanism of action, binding with high affinity to IL-13 and slow dissociation rate1-12.
This Class for
- Physician
- Resident / Fellow
What I will learn?
Enhance awareness and clinical understanding among targeted healthcare professionals regarding Atopic Dermatitis (AD) and the differentiated role of Ebglyss (lebrikizumab) in the management of moderate-to-severe AD.
Disclaimer
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)
For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
Please go to PDF Material for prescribing information
PP-LK-SA-0032
Related Classes
- Stable Response to IL-13 and IL-13/4 Inhibitor Treatment in Moderate-to- Severe AD.
- How Can Response Patterns to Olumiant Inform Clinical Decision-Making in Severe Alopecia Areata?
- Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Novel Treatment Option for Patients ≥12 Years
- Atopic Dermatitis in Elderly Patients: Discussing the Safety of Lebrikizumab in an 86-Year-Old Patient.
- Key IL-13 Skin and Itch Data in Moderate-to-Severe AD.
- Atopic Dermatitis in Visible Areas Is a Real Challenge!
- Depth of Response & Stability of Response of Lebrikizumab
- Can You Reach EASI Targets Faster? – AD Case with Prof. Naiem Issa